India, June 2 -- Drug major Eli Lilly and Co. (LLY) announced Monday new Phase 1 data showing that its investigational, next-generation folate receptor alpha or FRa antibody-drug conjugate or ADC, LY4170156, demonstrated an encouraging safety profile and anti-tumor activity in ovarian cancer trial.
The positive data was across dose and FRa expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine.
The company noted that a preliminary overall objective response rate or ORR of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg.
LY4170156 is an investigational, next-generation ADC targeting Fra, a cell-surface glycoprotein en...